Champix® (varenicline tartrate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Champix (varenicline tartrate), a medication indicated for smoking cessation in adults, is unavailable because a Class 2 medicine recall is in place.
Upon request from the Medicines & Healthcare products Regulatory Agency (MHRA), Pfizer Ltd is recalling all Champix stock as a precautionary measure due to presence of levels of N-nitroso-varenicline above the acceptable level of intake set by both European Medicines Agency (EMA) and MHRA. The recall is at pharmacy and wholesaler level.
Until the Champix shortage is resolved, patients will need to consult with their healthcare professional to choose an alternative treatment option.
Download here the full Dear Healthcare Professional Communication (DHPC) agreed with the MHRA.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021